Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer

Abstract Based on our previous phase II clinical trial of anti-programmed death-1 (PD-1) antibody nivolumab for platinum-resistant ovarian cancer (n = 19, UMIN000005714), we aimed to identify the biomarkers predictive response. Tumor gene expression was evaluated by proliferative, mesenchymal, differentiated, and immunoreactive signatures derived from high-grade serous carcinomas a signature established prior clear cell carcinoma. Resulting scores were statistically assessed with both univariate multivariate approaches correlation Analyses performed pathways differentially expressed either complete response (CR) or progressive disease (PD) patient groups. The scored significantly higher in CR group, proliferative had PD group where not effective (respective p values 0.005 0.026). Combinations improved response, visual projection immunoreactive, differentiated An applicable prediction formula derived. Ovarian cancer-specific related pathway provide robust preliminary indicator patients anti-PD-1 therapy decisions.